California Public Employees Retirement System grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 14.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 126,700 shares of the biopharmaceutical company’s stock after acquiring an additional 15,900 shares during the quarter. California Public Employees Retirement System owned about 0.15% of Alnylam Pharmaceuticals worth $10,106,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 6.3% during the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock valued at $1,094,559,000 after acquiring an additional 815,270 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 13.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock valued at $512,020,000 after acquiring an additional 759,295 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 5.0% during the 2nd quarter. Northern Trust Corp now owns 377,020 shares of the biopharmaceutical company’s stock valued at $30,072,000 after acquiring an additional 17,862 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $575,000. Finally, Van ECK Associates Corp boosted its holdings in shares of Alnylam Pharmaceuticals by 24.6% during the 2nd quarter. Van ECK Associates Corp now owns 128,050 shares of the biopharmaceutical company’s stock valued at $10,213,000 after acquiring an additional 25,273 shares during the last quarter. 94.25% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently issued reports on the stock. Goldman Sachs Group, Inc. (The) raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $62.00 to $163.00 in a report on Monday, October 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $56.00 price objective (up previously from $47.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Chardan Capital reissued a “buy” rating and issued a $124.00 price objective (down previously from $131.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, August 10th. Jefferies Group LLC raised their price objective on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, September 26th. Finally, Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the stock an “equal weight” rating in a report on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $100.80.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/08/alnylam-pharmaceuticals-inc-alny-stake-increased-by-california-public-employees-retirement-system.html.

In other news, President Barry E. Greene sold 85,316 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Barry E. Greene sold 76,815 shares of the stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the transaction, the president now owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. Company insiders own 4.30% of the company’s stock.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at 122.65 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $31.38 and a 52-week high of $125.96. The company’s market cap is $11.25 billion. The stock’s 50 day moving average is $94.74 and its 200 day moving average is $74.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. During the same quarter last year, the business earned ($1.05) EPS. The company’s quarterly revenue was up 82.9% on a year-over-year basis. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.20) EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.